Three European Nations Achieve 90 Percent HPV Vaccination Milestone as ECDC Reports Major Decline in Cervical Cancer Rates

ECDC report shows Iceland, Portugal, and Norway reached top HPV vaccine targets, with Sweden reporting an 88% drop in cancer for those vaccinated early.

By: AXL Media

Published: Apr 20, 2026, 8:39 AM EDT

Source: Information for this report was sourced from EurekAlert!

Strategic Progress in Continental Cancer Prevention

As the region observes European Immunization Week 2026, the European Centre for Disease Prevention and Control (ECDC) has announced a significant breakthrough in the fight against viral-induced cancers. For the first time, all countries within the European Union and European Economic Area have officially integrated HPV vaccination recommendations for both adolescent girls and boys into their national health frameworks. This unified policy shift marks a definitive transition in European public health, prioritizing preventative oncology as a standard of care for the next generation.

Leading Nations and the Ninety Percent Threshold

The ECDC report highlights a trio of countries Iceland, Portugal, and Norway as the regional leaders in vaccine adoption, having successfully met the 90% coverage target for girls by the age of 15. This specific metric was established by the 2024 EU Council Recommendation as a critical benchmark for achieving herd immunity and long-term disease suppression. According to Bruno Ciancio, Head of Unit at the ECDC, the elimination of cervical cancer is no longer a theoretical aspiration but an achievable public health goal, provided that countries maintain consistent investment in their immunization infrastructure.

Quantifiable Reductions in Invasive Disease Incidence

Fifteen years after the initial rollout of these programs, longitudinal data from Sweden, Denmark, and the United Kingdom provides empirical evidence of the vaccine's efficacy. A landmark Swedish study indicated that administering the vaccine before a girl's 17th birthday resulted in an 88% reduction in the incidence of cervical cancer. Furthermore, a six-year follow-up period confirmed a sustained decline in invasive cases at the population level, illustrating that early intervention provides the most robust protective potential against future precancerous lesions and chronic HPV infections.